Evaluation of red blood cell lipoperoxidation in hemodialysed patients during erythropoietin therapy supplemented or not with iron
To investigate the effects of erythropoietin (rHuEPO) therapy supplemented or not with iron on hemolysis in hemodialysed patients (HD) we evaluated lipoperoxidation (LPO) by assaying (i) the red blood cell (RBC) antioxidant enzymatic system including superoxide dismutase (SOD), glutathione peroxidas...
Saved in:
Published in | Nephron (2015) Vol. 69; no. 4; p. 404 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
1995
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | To investigate the effects of erythropoietin (rHuEPO) therapy supplemented or not with iron on hemolysis in hemodialysed patients (HD) we evaluated lipoperoxidation (LPO) by assaying (i) the red blood cell (RBC) antioxidant enzymatic system including superoxide dismutase (SOD), glutathione peroxidase, and catalase (Cat), (ii) RBC polyunsaturated fatty acids (PUFA) and (iii) malondialdehyde (MDA). Group 1 included 12 HD patients, group 2 had 7 HD patients with iron supplementation, group 3 comprised 12 HD patients with rHuEPO therapy and group 4 included 9 HD patients with both iron and rHuEPO therapies. No LPO was found in group 1 as regards MDA and PUFA levels. However, SOD and Cat activities were significantly elevated as compared to controls (p < 0.001). In the second group, a significant decrease in PUFA percentage was observed, particularly in 20:4(n-6) and 22:4(n-6) (the main ones involved in LPO) as compared to the other groups, whereas total MDA level was higher than that of the other groups. Similarly a decreased SOD activity was observed as compared to group 1 (p < 0.001), indicating its inactivation subsequent to an hyperproduction of reactive oxygen species through iron injection. In groups 3 and 4 no change was observed in MDA levels or PUFA percentages indicating no LPO. However, marked differences were observed in the enzymatic defense system. Particularly in group 3, SOD and Cat activities decreased when compared to group 1 (p < 0.001) whereas the association of erythropoietin and iron (group 4) increased the three enzymatic activities (p < 0.001). |
---|---|
AbstractList | To investigate the effects of erythropoietin (rHuEPO) therapy supplemented or not with iron on hemolysis in hemodialysed patients (HD) we evaluated lipoperoxidation (LPO) by assaying (i) the red blood cell (RBC) antioxidant enzymatic system including superoxide dismutase (SOD), glutathione peroxidase, and catalase (Cat), (ii) RBC polyunsaturated fatty acids (PUFA) and (iii) malondialdehyde (MDA). Group 1 included 12 HD patients, group 2 had 7 HD patients with iron supplementation, group 3 comprised 12 HD patients with rHuEPO therapy and group 4 included 9 HD patients with both iron and rHuEPO therapies. No LPO was found in group 1 as regards MDA and PUFA levels. However, SOD and Cat activities were significantly elevated as compared to controls (p < 0.001). In the second group, a significant decrease in PUFA percentage was observed, particularly in 20:4(n-6) and 22:4(n-6) (the main ones involved in LPO) as compared to the other groups, whereas total MDA level was higher than that of the other groups. Similarly a decreased SOD activity was observed as compared to group 1 (p < 0.001), indicating its inactivation subsequent to an hyperproduction of reactive oxygen species through iron injection. In groups 3 and 4 no change was observed in MDA levels or PUFA percentages indicating no LPO. However, marked differences were observed in the enzymatic defense system. Particularly in group 3, SOD and Cat activities decreased when compared to group 1 (p < 0.001) whereas the association of erythropoietin and iron (group 4) increased the three enzymatic activities (p < 0.001). |
Author | Dubourg, L Peuchant, E Clerc, M de Précigout, V Carbonneau, M A Aparicio, M Delmas-Beauvieux, M C Combe, C |
Author_xml | – sequence: 1 givenname: M C surname: Delmas-Beauvieux fullname: Delmas-Beauvieux, M C organization: Laboratoire de Biochimie Médicale A, Université de Bordeaux II, France – sequence: 2 givenname: C surname: Combe fullname: Combe, C – sequence: 3 givenname: E surname: Peuchant fullname: Peuchant, E – sequence: 4 givenname: M A surname: Carbonneau fullname: Carbonneau, M A – sequence: 5 givenname: L surname: Dubourg fullname: Dubourg, L – sequence: 6 givenname: V surname: de Précigout fullname: de Précigout, V – sequence: 7 givenname: M surname: Aparicio fullname: Aparicio, M – sequence: 8 givenname: M surname: Clerc fullname: Clerc, M |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/7777104$$D View this record in MEDLINE/PubMed |
BookMark | eNot0MtKxDAUBuAgI2MdZ-EDCHmBak6S3pYyjBcYcKPrIW1SG0mTkKZqtz65gZmzOfDznX9xrtHKOqsQugVyD1A0D4QQqOsCyAXKKGVFzqAuVyiDsiR5DQVcoe00fSVGGbCG8TVaV2mA8Az97b-FmUXUzmLX46Akbo1zEnfKGGy0d14F96vliWiLBzU6qYVZpmR9ipWNE5Zz0PYTq7DEITjvtIrJxkEF4Rc8zd4bNSaZblzA1kX8o-OAdXD2Bl32wkxqe94b9PG0f9-95Ie359fd4yHvaMVi3tKOyULUDfSd6EQvRQWiragCBbzikvGqbuqybFkFHW8bVgieJCWsEwR6Rjfo7tTr53ZU8uiDHkVYjudf0H88wGYi |
CitedBy_id | crossref_primary_10_1111_j_1440_1797_2002_tb00506_x crossref_primary_10_1016_j_hoc_2013_11_002 crossref_primary_10_1016_S0891_5849_96_00282_1 crossref_primary_10_1016_j_cbi_2009_06_007 crossref_primary_10_1038_sj_ki_5002482 crossref_primary_10_1046_j_1523_1755_2000_00443_x crossref_primary_10_1016_j_foodchem_2015_06_088 crossref_primary_10_1038_ki_1997_466 crossref_primary_10_1111_j_1525_1594_2004_29011_x crossref_primary_10_1080_10715769800300011 crossref_primary_10_3390_nu10101353 crossref_primary_10_1046_j_1440_1797_7_s_2_x crossref_primary_10_1203_01_PDR_0000146032_98120_43 crossref_primary_10_14302_issn_2574_4488_jna_19_3112 crossref_primary_10_1081_JDI_120002663 crossref_primary_10_1016_j_nut_2012_06_002 crossref_primary_10_1111_j_1492_7535_2005_01116_x crossref_primary_10_1046_j_1525_139X_1999_99028_x crossref_primary_10_1074_jbc_274_27_18916 crossref_primary_10_1152_ajprenal_00200_2006 crossref_primary_10_1097_00002480_200009000_00023 crossref_primary_10_1111_trf_15257 crossref_primary_10_1111_j_1440_1797_2004_00262_x crossref_primary_10_1177_039139889902200203 crossref_primary_10_1186_1471_2431_5_29 crossref_primary_10_1111_j_1542_4758_2007_00144_x crossref_primary_10_1046_j_1523_1755_2003_00741_x crossref_primary_10_1093_ajcn_64_5_757 crossref_primary_10_1046_j_1525_1594_2003_07170_x crossref_primary_10_1097_00002480_200109000_00024 crossref_primary_10_1016_j_fct_2012_01_042 crossref_primary_10_1016_S0006_2952_99_00277_4 crossref_primary_10_1046_j_1525_1594_1999_06328_x crossref_primary_10_1093_ndt_16_2_335 crossref_primary_10_1155_2010_978710 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1159/000188510 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
EISSN | 2235-3186 |
ExternalDocumentID | 7777104 |
Genre | Clinical Trial Controlled Clinical Trial Journal Article |
GroupedDBID | 0R~ 30W 327 4.4 53G 7X7 88E 8AO 8FI 8FJ ABUWG ACGFS ADBBV AENEX AFKRA AFOSN ALMA_UNASSIGNED_HOLDINGS AZPMC BENPR BPHCQ BVXVI CCPQU CGR CUY CVF CYUIP EBS ECM EIF EJD EMB EMOBN F5P FYUFA HMCUK HZ~ KUZGX M1P NPM O1H O9- PQQKQ PROAC PSQYO RKO RXVBD S0X SV3 UKHRP |
ID | FETCH-LOGICAL-c273t-b2c3d5a891fcacafda71ab72e1e1474d34789866b371c4b935a4fca203ca01f32 |
ISSN | 1660-8151 |
IngestDate | Fri May 24 00:04:13 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c273t-b2c3d5a891fcacafda71ab72e1e1474d34789866b371c4b935a4fca203ca01f32 |
PMID | 7777104 |
ParticipantIDs | pubmed_primary_7777104 |
PublicationCentury | 1900 |
PublicationDate | 1995-00-00 |
PublicationDateYYYYMMDD | 1995-01-01 |
PublicationDate_xml | – year: 1995 text: 1995-00-00 |
PublicationDecade | 1990 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Nephron (2015) |
PublicationTitleAlternate | Nephron |
PublicationYear | 1995 |
SSID | ssj0002313934 |
Score | 1.6461267 |
Snippet | To investigate the effects of erythropoietin (rHuEPO) therapy supplemented or not with iron on hemolysis in hemodialysed patients (HD) we evaluated... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 404 |
SubjectTerms | Adult Aged Anemia - blood Anemia - drug therapy Anemia - etiology Catalase - blood Erythrocytes - drug effects Erythrocytes - metabolism Erythropoietin - therapeutic use Fatty Acids, Unsaturated - blood Female Glutathione Peroxidase - blood Humans Iron - administration & dosage Lipid Peroxidation - drug effects Male Malondialdehyde - blood Middle Aged Renal Dialysis - adverse effects Superoxide Dismutase - blood Uremia - blood Uremia - complications Uremia - therapy |
Title | Evaluation of red blood cell lipoperoxidation in hemodialysed patients during erythropoietin therapy supplemented or not with iron |
URI | https://www.ncbi.nlm.nih.gov/pubmed/7777104 |
Volume | 69 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Rb9MwELY6ENJe0BBMMDbkB96iQBw7cfI4YGhCouJhk_Y22Y4jitakahOJ8rh_s3-5O9tt0zIkIA9RZDtW6vtyvlzvviPkLewCGnblKlayymMB70SsS2VjpBZJy1Qj4QdGW4zz80vx5Sq7Go3uBlFLfaffmV8P5pX8j1ShDeSKWbL_INn1pNAA1yBfOIOE4fxXMj5bU3WjzYeR5C4OPUJvfHQzmbXIAv5z4ssmoWfju522mCmyXMDYQKm6WKUq2vnSF02YYBp05DOzltEC6346JyLc086jpu289xYT5Ia27djOkGkXbVbY77OBj-GTvZmqRfzBqh624d7td183_lnQSdpueWy_2R4zkrvtVAk11xiWo3p__-nGY-EzwNceC69k8zyJCxaIZq1rAysF_5EPtNhBM_siLgGBYqBmhS9Z_Lv6z0ofL8kKsCST4RiQ3GzqcCDhYNsTPNi5w8MdevbInixQlY6DW-iH4wwCQ9pHMKx-W2Cxgid6v36effIkzLLzEeOMmYsD8jR8hdBTD6lnZGSb5-R2Ayfa1hTgRB2cKMKJ7sKJTho6hBNdwYl6ONFtONEAJzqEE23nFOBEEU4U4fSCXH4-u_h4HocSHbEBu7eLdWp4lamiZLVRRtWVkkxpmVpmmZCi4kIWZZHnmktmhC55pgSMTBNuVMJqnh6SR03b2JdIHgCLlCJ9ZKLAssoU56awqeamrGsr81fk0C_Z9czzsFyHtTz6U8drsr-B3zF5XMNrb0_Ahuz0Gye_e403c98 |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+red+blood+cell+lipoperoxidation+in+hemodialysed+patients+during+erythropoietin+therapy+supplemented+or+not+with+iron&rft.jtitle=Nephron+%282015%29&rft.au=Delmas-Beauvieux%2C+M+C&rft.au=Combe%2C+C&rft.au=Peuchant%2C+E&rft.au=Carbonneau%2C+M+A&rft.date=1995-01-01&rft.issn=1660-8151&rft.eissn=2235-3186&rft.volume=69&rft.issue=4&rft.spage=404&rft_id=info:doi/10.1159%2F000188510&rft_id=info%3Apmid%2F7777104&rft_id=info%3Apmid%2F7777104&rft.externalDocID=7777104 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1660-8151&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1660-8151&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1660-8151&client=summon |